7607.TWO
Price:
$19.5
Market Cap:
$693.28M
Duogenic Stemcells Corp. engages in the provision of biotechnology and medical care services. It offers closed culture cell system and cell therapy services. The company was founded on March 22, 2018 and is headquartered in Taichung, Taiwan.
Industry
Medical - Specialties
IPO Date
2023-05-25
Stock Exchange
TWO
Ticker
7607.TWO
According to DuoGenic StemCells corporation’s latest financial reports and current stock price. The company's current PE Ratio is -13.64. This represents a change of 71.54% compared to the average of -7.95 of the last 4 quarters.
The mean historical PE Ratio of DuoGenic StemCells corporation over the last ten years is -40.66. The current -13.64 PE Ratio has changed 3.25% with respect to the historical average. Over the past ten years (40 quarters), 7607.TWO's PE Ratio was at its highest in in the June 2025 quarter at -5.47. The PE Ratio was at its lowest in in the June 2022 quarter at -30.44.
Average
-40.66
Median
-38.89
Minimum
-73.39
Maximum
-11.46
Discovering the peaks and valleys of DuoGenic StemCells corporation PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -11.46
Minimum Annual Increase = -54.02%
Minimum Annual PE Ratio = -73.39
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -11.46 | -53.22% |
| 2023 | -24.50 | -54.02% |
| 2022 | -53.28 | -27.41% |
The current PE Ratio of DuoGenic StemCells corporation (7607.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-29.75
5-year avg
-40.66
10-year avg
-40.66
DuoGenic StemCells corporation’s PE Ratio is greater than EPS Bio Technology Corp. (-28.64), less than Taiwan Advanced Nanotech Inc. (-2.28), less than UniPharma Co., Ltd. (-10.97), less than Pharmigene, Inc. (-6.95), greater than Sunder Biomedical Tech. Co., Ltd. (-50.25), less than Welgene Biotech Co.,Ltd. (185.95), less than A-SPINE Asia Co., Ltd. (53.12), greater than Health & Life Co., Ltd. (-37.83), less than iXensor Co., Ltd. (-4.30), greater than Vectorite Biomedical Inc. (-27.18),
| Company | PE Ratio | Market cap |
|---|---|---|
| -28.64 | $404.60M | |
| -2.28 | $460.98M | |
| -10.97 | $426.01M | |
| -6.95 | $524.90M | |
| -50.25 | $511.20M | |
| 185.95 | $436.95M | |
| 53.12 | $531.43M | |
| -37.83 | $530.97M | |
| -4.30 | $256.33M | |
| -27.18 | $630.31M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DuoGenic StemCells corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like DuoGenic StemCells corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is DuoGenic StemCells corporation's PE Ratio?
How is the PE Ratio calculated for DuoGenic StemCells corporation (7607.TWO)?
What is the highest PE Ratio for DuoGenic StemCells corporation (7607.TWO)?
What is the 3-year average PE Ratio for DuoGenic StemCells corporation (7607.TWO)?
What is the 5-year average PE Ratio for DuoGenic StemCells corporation (7607.TWO)?
How does the current PE Ratio for DuoGenic StemCells corporation (7607.TWO) compare to its historical average?